14/06/2026 Eli Lilly's Jaypirca Cuts Disease Progression Risk by 45% in Previously Treated CLL/SLL Eli Lilly's Jaypirca Cuts Disease Progression Risk by 45% in Previously Treated CLL/SLL (Ref) Eli Lilly announced positive Phase 3 BRUIN CLL-322 results for Jaypirca (pirtobrutinib) combined with venetoclax and rituximab in relapsed/refractory CLL/SLL, meeting its primary endpoint with a statistically significant 45% reduction in disease progression or death compared to venetocl

16/02/2026 Phase 3 LIBRETTO-432 trial of adjuvant selpercatinib met the EFS endpoint in RET fusion positive NSCLC Phase 3 LIBRETTO-432 trial of adjuvant selpercatinib met the EFS endpoint in RET fusion positive NSCLC (Ref) Eli Lilly and Company announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of selpercatinib (Retevmo; RET kinase inhibitor) as an adjuvant therapy versus placebo in patients with early-stage (II-IIIA) RET fusion-positive NSCLC. Th

15/12/2025 Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan + pertuzumab has been approved for first-line HER2+ve breast cancer FibroGen's roxadustat received the FDA Orphan Drug Designation for myelodysplastic syndromes Eli Lilly's TECVAYLI plus DARZALEX FASPRO combo has been selected for the FDA's CNPV Pilot program Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan + pertuzumab has been approved for first-line HER2+ve breast cancer (Ref) The US FDA granted appr

03/12/2025 Eli Lilly and Company's pirtobrutinib received the FDA approval for R/R CLL/SLL Eli Lilly and Company's pirtobrutinib received the FDA approval for R/R CLL/SLL (Ref) The US FDA granted approval to Eli Lilly and Company's pirtobrutinib (Jaypirca; BTK inhibitor) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. This approval conve

25/09/2025 Eli Lilly and Company's Inluriyo has been approved in the US for ER+, HER2–, ESR1-mutated breast cancer (Ref) The US FDA approved Eli Lilly and Company's Inluriyo (imlunestrant, oral estrogen receptor antagonist) for the treatment of adults with ER+, HER2–, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The FDA approval is based on the results of the Phase 3 EMBER-3 trial Inluriyo reduced the

04/09/2025 Eli Lilly and Company's olomorasib in combination with Keytruda received the FDA Breakthrough Therapy designation for metastatic KRAS G12C-mutant NSCLC (Ref) The US FDA granted the Breakthrough Therapy designation to Eli Lilly and Company's olomorasib (KRAS G12C inhibitor) + Merck & Co/MSD's pembrolizumab (anti-PD-1), for the first-line treatment of unresectable advanced or metastatic NSCLC with a KRAS G12C mutation and PD-L1 expression ≥ 50%. The designation was b

Esophageal cancer is the fourteenth most commonly diagnosed cancer and the eighth leading cause of cancer-related death worldwide. The burden of esophageal cancer incidence and mortality is steadily increasing worldwide due to increased prevalence of associated risk factors such as tobacco and alcohol consumption, poor diet, sedentary lifestyle and obesity. Despite advancements in targeted therapies and immunotherapies, the prognosis of Esophageal cancer remains dismal, with

Gastric cancer has remained one of the leading causes of cancer-related deaths globally. It was reported as the 5th most common cancer and the 4th leading cause of cancer death worldwide in 2020, with an observed trend of increasing incidence rates in younger adults (<50 years). Despite therapeutic progress, the survival rate for gastric cancer patients remains low, highlighting the unmet need for treatments of further potential. In this concise infographic, we highlight the

Thyroid Cancer, despite a good prognosis, has been a cause of concern over the past years. Thyroid Cancer shows no symptoms in the early stage, but its increasing rate of occurrence indicates the need for further diagnostic and therapeutic options. In observance of Thyroid Cancer Awareness month, Oncofocus is pleased to present an infographic highlighting the key options with a glimpse of the emerging therapies in the Thyroid cancer treatment paradigm.